tbuckley/cabot-search huggingface dataset:
Take home naloxone for opiate addicts
Authors: C. A Graham, G. W McNaughton, A. J Ireland, K. Cassells, D. Mountain, G. Blackwood, A J Ashworth, A Kidd, J. Strang
Journal: BMJ (2001)

Editor—Dettmer et al report encouraging initial results of a scheme to give take home naloxone to opiate addicts.1 They also refer to training opiate misusers in resuscitation as part of the project. In 1997 we conducted a pilot study of cardiopulmonary resuscitation training in Glasgow, where the incidence of sudden death due to drug misuse is high.

Of the nine volunteers who agreed to participate in the study (all opiate misusers), eight had witnessed a drug overdose. Six described unconsciousness and seven described cyanosis in the victims. The methods used to stimulate the victims ranged from physical stimulation (for example, slapping) (n=6) to injecting intravenous amphetamine (n=1) or using a spoon to prevent tongue swallowing (n=1). Emergency services had been called in five cases. Only one volunteer reported attempting cardiopulmonary resuscitation.

All volunteers were assessed with a validated scoring system before and after a standard basic life support teaching session.2 The group's mean penalty score fell from 94 (range 25-120) to 11 (range 0-20) (P<0.001, paired t test for sample means). The two instructors who did the testing and training confirmed that in the test after the instruction all volunteers performed to the standard expected for the Resuscitation Council (UK) advanced life support course.

Most drug misusers in our pilot study had witnessed an overdose, and take home naloxone or cardiopulmonary resuscitation may therefore be useful in Glasgow. We are concerned that not all the misusers called for immediate help, but other studies have suggested that this may be due to fear of the police becoming involved.3

Our pilot study showed that this vulnerable group can be trained in basic life support to an acceptable level. If enough drug misusers could be trained in cardiopulmonary resuscitation this might be a useful additional strategy to reduce mortality from opiate overdose.
Development of the functional assessment of cancer therapy-immune checkpoint modulator (FACT-ICM): A scale to measure quality of life in cancer patients treated with ICMs
Authors: A.R. Hansen, K. Ala-leppilampi, C. McKillop, L.L. Siu, P. Bedard, A R Abdul Razak, A. Spreafico, S. Sridhar, N.B. Leighl, M.O. Butler, D. Hogg, A. Sacher, A.M. Oza, R. Nisenbaum, K.A. Webster, D. Cella, J. Parsons
Journal: Annals of Oncology (2019)
Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity
Authors: Jacqulyne P. Robichaux, Yasir Y. Elamin, R.S.K. Vijayan, Monique B. Nilsson, Lemei Hu, Junqin He, Fahao Zhang, Marlese Pisegna, Alissa Poteete, Huiying Sun, Shuai Li, Ting Chen, Han Han, Marcelo Vailati Negrao, Jordi Rodon Ahnert, Lixia Diao, Jing Wang, Xiuning Le, Funda Meric-Bernstam, Mark Routbort, Brent Roeck, Zane Yang, Victoria M. Raymond, Richard B. Lanman, Garrett M. Frampton, Vincent A. Miller, Alexa B. Schrock, Lee A. Albacker, Kwok-kin Wong, Jason B. Cross, John V. Heymach
Journal: Cancer Cell (2019)
CCTG IND 232: A phase II study of durvalumab with or without tremelimumab in patients with metastatic castration resistant prostate cancer (mCRPC)
Authors: S.J. Hotte, E. Winquist, K.N. Chi, S.L. Ellard, S. Sridhar, U. Emmenegger, M. Salim, N.N. Iqbal, C. Canil, C.K. Kollmannsberger, A.R. Hansen, A-K A Lalani, J. Gingerich, D. Finch, M. Cabanero, A.W. Wyatt, D. Tu, F. Vera-Badillo, L.K. Seymour, M. Smoragiewicz
Journal: Annals of Oncology (2019)
Clinical profile and outcome of HER2 positive breast cancer patients with brain metastases treated with HER2 targeted therapy: Real-world experience
Authors: P.G. Bhargava, R. Shenoy, N. Rathnasamy, S. Gulia, J. Bajpai, J. Ghosh, S. Rath, A. Budrukkar, T. Shet, A. Patil, N. Nair, P. Popat, T. Wadasadawala, R. Sarin, S. Kannan, R. Badwe, S. Gupta
Journal: Annals of Oncology (2019)
Efficacy of weekly paclitaxel-bevacizumab combination in advanced non squamous non-small cell lung cancer (NSCLC): A retrospective multicentric study
Authors: G. Bilger, P. Boré, S. Valery, J. Pinsolle, R. Descourt, M. Geier, I. Monnet, A.C. Toffart, V. Bocquillon, G. Rousseau Bussac, C. Chouaid, G. Robinet, F. Ennahdi, I. Zaccaria, C. Decroisette
Journal: Annals of Oncology (2019)
Recent developments and highlights in allergic rhinitis
Authors: Yifan Meng, Chengshuo Wang, Luo Zhang
Journal: Allergy (2019)

Abstract Allergic rhinitis (AR) is a disease with high prevalence all over the world and therefore needs to be thoroughly investigated and treated accordingly. The mechanisms underlying the pathology and treatment of AR have been widely studied, but many aspects remain unclear and warrant further investigations. This review presents an overview of recently published papers highlighting the risk factors, mechanisms, and treatment of AR. Additionally, recent studies discussing the role of single nucleotide polymorphism, DNA methylation, regulatory B cells, group 2 innate lymphoid cells, immunotherapy, and biologics in AR are also covered.
Clinical confirmation of higher exposure to niraparib in tumour vs plasma in patients with breast cancer
Authors: L. Spring, M. Shan, M.C. Liu, E. Hamilton, C.A. Santa-Maria, H. Irie, S. Isakoff, J. Reeves, L.W. Ellisen, A. Liem, A Milillo Naraine, J. Nangia, D. Page, P. Pan, K. Sun, J.R. Graham, H. Han
Journal: Annals of Oncology (2019)
Primary ovarian carcinomas arising in BRCA1 mutation carriers contain a small fraction of BRCA1-proficient cells, which rapidly repopulate tumor mass during neoadjuvant chemotherapy but become outgrown by BRCA1-deficient clones during platinum-free intervals
Authors: E. Imyanitov, A. Sokolenko, T. Gorodnova, E. Savonevich, A. Ivantsov, E. Preobrazhenskaya, A. Togo, I. Berlev
Journal: Annals of Oncology (2019)
Activated effector T cells co-expressing multiple inhibitory receptors (IRs) are enriched in the tumor immune microenvironment in high grade serous ovarian cancer (HGSOC)
Authors: A. Bergamini, E. Tassi, J. Wignall, L. Bocciolone, M. Candiani, A. Potenza, F. Manfredi, G. Taccagni, F. Scalisi, C. Doglioni, G. Mangili, C. Bonini
Journal: Annals of Oncology (2019)
TCT-157 Gender-dependent impact of ESC-guidelines recommended times to reperfusion therapy in STEMI patients undergoing primary percutaneous coronary intervention: analysis of an 8-year all-comers registry
Authors: Alfredo Redondo Diéguez, Ramiro Trillo Nouche, Alejandro Avila Carrillo, Diego Lopez Otero
Journal: Journal of the American College of Cardiology (2017)
Thyroid Hormone Action at the Cell Level
Authors: Kenneth Sterling
Journal: New England Journal of Medicine (1979)

IT is possible to divide hormones into two classes1 on the basis of physical-chemical characteristics (Table 1). The protein and peptide hormones are virtually infinitely soluble in aqueous solution, unlike the hydrophobic (small molecule) "target" hormones, which exist in solution by virtue of being bound by albumin and specific transport proteins. The sex-hormone-binding globulin, transcortin or corticosteroid-binding globulin (CBG), and thyroxine-binding α-globulin (TBG) are the carriers of the hydrophobic secretions of the gonads, the adrenal and thyroid glands, the "target" glands of the pituitary tropic hormones. Protein and peptide hormones, such as growth hormone, the pituitary . . .
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
Authors: Scott Kopetz, Axel Grothey, Rona Yaeger, Eric Van Cutsem, Jayesh Desai, Takayuki Yoshino, Harpreet Wasan, Fortunato Ciardiello, Fotios Loupakis, Yong Sang Hong, Neeltje Steeghs, Tormod K. Guren, Hendrik-Tobias Arkenau, Pilar Garcia-Alfonso, Per Pfeiffer, Sergey Orlov, Sara Lonardi, Elena Elez, Tae-Won Kim, Jan H.M. Schellens, Christina Guo, Asha Krishnan, Jeroen Dekervel, Van Morris, Aitana Calvo Ferrandiz, L.S. Tarpgaard, Michael Braun, Ashwin Gollerkeri, Christopher Keir, Kati Maharry, Michael Pickard, Janna Christy-Bittel, Lisa Anderson, Victor Sandor, Josep Tabernero
Journal: New England Journal of Medicine (2019)

Patients with metastatic colorectal cancer with the BRAF V600E mutation have a poor prognosis, with a median overall survival of 4 to 6 months after failure of initial therapy. Inhibition of BRAF alone has limited activity because of pathway reactivation through epidermal growth factor receptor signaling.
Long-term results of phase II trial of reduced modified clinical target volume in low-risk nasopharyngeal carcinoma treated with intensity modulated radiotherapy
Authors: J. Miao, M. Di, Y. Cao, L. Wang, W. Xiao, M. Zhu, B. Chen, S. Huang, F. Han, X. Deng, Y. Xiang, M.L.K. Chua, X. Guo, C. Zhao
Journal: Annals of Oncology (2019)
The First Deletion Mutation in the TSP1-6 Repeat Domain of ADAMTS13 Leads to a Secretion Defect.
Authors: Flora Peyvandi, Silvia Lavoretano, Roberta Palla, Isabella Garagiola, Carla Valsecchi, Rossana Lombardi, Maria T. Canciani, Pier M. Mannucci
Journal: Blood (2005)
Survival Outcome of Salvage Therapy with Second-Generation Novel Agents in Patients with Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice
Authors: Shuji Ozaki, Takeshi Harada, Kengo Udaka, Etsuko Sekimoto, Hironobu Shibata, Toshio Shigekiyo, Hikaru Yagi, Yasunobu Okamoto, Kimiko Sogabe, Masahiro Oura, Shiro Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Masahiro Abe
Journal: Blood (2018)
A NOVEL GRASPING-TYPE SCISSORS FORCEPS ALLOWS FOR FAST, SAFE AND EFFECTIVE ENDOSCOPIC MYOTOMY IN PATIENTS WITH ZENKER'S DIVERTICULUM
Authors: T Rath, J Siebler, MF Neurath, A Nägel
Journal: Endoscopy (2018)

Several endoscopic techniques have been described for Zenker's diverticulotomy; however, no standardized endoscopic approach has been routinely established yet. This study aimed to assess the efficacy and safety of endoscopic diverticulotomy using the Clutch Cutter (CC) as a novel grasping-type scissors forceps.
ASSERT: A prospective, observational study measuring sodium improvement and outcomes in patients treated for moderate to severe hyponatremia secondary to syndrome of inappropriate antidiuretic hormone secretion (SIADH) in Italy (lung cancer cohort)
Authors: R. Berardi, G. Lo Russo, M. Tiseo, L. Cavanna, D. Ferrari, E. Rijavec, G. Altavilla, A. Morabito, G. Pinotti, R. Buosi, M. Scartozzi, C. Ferrara, M.G. Giustra, R. Evans, V. De Marino
Journal: Annals of Oncology (2019)
Comparative analysis of tumour mutational burden (TMB) prediction methods and its association with determinants of the tumour immune microenvironment of urothelial bladder cancer (UBC)
Authors: M. Eckstein, A. Hartmann, P. Strissel, R. Strick, S. Wach, H. Taubert, B. Wullich, C. Geppert, V. Weyerer, R. Stoehr, M. Rübner, P.A. Fasching, S. Rabizadeh, S. Benz, F. Haller, E. Moskalev, L. Toegel
Journal: Annals of Oncology (2019)
BRCA testing of 1,284 Brazilian patients for hereditary breast and ovarian cancer in a routine diagnostic setting
Authors: F. Milanezi, J.S. Silva, S.M. de Marsillac, P.M. Monfredini, V. Nakano, M.G. D’Andrea, R. Guarischi-Sousa, B. Schnabel, W.D. Correia, G.A. Campana, G.G. da Fonseca, E. Perrone, I. Zalcberg
Journal: Annals of Oncology (2019)
PAM50 HER2-enriched subtype and pathological complete response in HER2-positive early breast cancer: A meta-analysis
Authors: F. Schettini, T. Pascual, N. Chic, B. Conte, O. Martínez, B. Adamo, M. Vidal, M. Muñoz, A. Fernández-Martínez, G. Griguolo, V. Guarneri, P.F. Conte, S. De Placido, L. Carey, C.M. Perou, A. Prat
Journal: Annals of Oncology (2019)
Retention of CD19 intron 2 contributes to CART-19 resistance in leukemias with subclonal frameshift mutations in CD19
Authors: Mukta Asnani, Katharina E. Hayer, Ammar S. Naqvi, Sisi Zheng, Scarlett Y. Yang, Derek Oldridge, Fadia Ibrahim, Manolis Maragkakis, Matthew R. Gazzara, Kathryn L. Black, Asen Bagashev, Deanne Taylor, Zissimos Mourelatos, Stephan A. Grupp, David Barrett, John M. Maris, Elena Sotillo, Yoseph Barash, Andrei Thomas-Tikhonenko
Journal: Leukemia (2019)

Every successful cancer therapy story has Exhibit B, comprised of patients who either did not respond to the initial treatment or acquired resistance after a seemingly curative intervention.The CD19-directed chimeric antigen receptorarmed T-cell therapy (commonly known as CART-19) is the case in point.Although it has revolutionized treatment for B-cell acute lymphoblastic leukemia (B-ALL) in children and adults and gained swift FDA approval, ~30% of patients relapse after complete responses, most often via the loss of the cognate CD19 epitope [1].Under selective pressure of CART-19 some of MLL-rearranged B-ALL have the propensity to trans-differentiate into myeloid lineages with concomitant loss of CD19 expression [reviewed in [2]].Transport of CD19 to the plasma membrane is another potentially vulnerable process [3] requiring the dedicated CD81 chaperone; and dysregulation of this gene was reported to contribute to resistance to another CD19-targeted immunotherapeutic blinatumumab [4].Still, focal alterations of the CD19 gene and its transcript appear to play central role in resistance [5].In December 2015 our group published in Cancer Discovery the first report addressing the mechanism of resistance to CART-19, based on the analysis of the first 4 patients enrolled in the clinical trial at the Children's Hospital of Philadelphia [6].We performed whole exome and RNA sequencing and immunoblotting on relapsed leukemias lacking the CART-19 epitope on the cell surface.We observed that "genetic alterations… accounted for CD19 protein loss in some… but not in other… samples".For example, in sample CHOP101R we discovered frameshift mutations in exons 2 and 4.However, both were subclonal and collectively accounted for no more than 50% of CD19 alleles, implying the existence of additional mechanisms of gene inactivation.Indeed, we discovered prominent splicing alterations involving increased skipping of exon 2 and exons 5-6 in relapsed leukemias; these preexisting isoforms were later reported by others as well [7].Of note, exon 2 is absolutely essential for the integrity of the CART-19 epitope [3] and exons 5-6 encode the CD19 transmembrane domain needed for presentation on the cell surface.Thus, our paper was entitled "Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy", stressing the importance of both DNA-and RNA-based mechanisms.
Tumour mutational burden and response to PD-1 inhibitors: An analysis of 89 cases of metastatic melanoma
Authors: L. Dousset, L. Boussemart, C. Robert, S. Mansard, C. Lebbe, J.-P. Merlio, E. Routier, A. Dupuy, J. Rouanet, M. Battistella, D. Capellen, M.-D. Galibert, C. Allayous, A. Lespagnol, G. Villechenoux, E. Gerard, I. Kerneuzet, S. Roy, B. Vergier, M. Beylot-Barry
Journal: Annals of Oncology (2019)
Abstract 18238: Cardiomyocyte-specific Bag3+ Mutation P209L Induces Mitochondrial Fragmentation, Increased Apoptosis, and Activates p38 Signaling in vivo
Authors: Megan T Quintana, Samuel C Eaton, Cecelia C Yates, Shinichi Takayama, Monte S Willis
Journal: Circulation (2015)

Introduction: There are 6 members of the Bcl2-related anthanogene (BAG) protein family, which act as co-chaperones expressed at high levels in skeletal and cardiac muscle. BAG3 is involved in chaperone-assisted selective autophagy (CASA). Mutations in the Z-disc protein BAG3 have recently been found to cause myofibrillar myopathy (MFM) with cardiac complications (dilated cardiomyopathy). The missense mutation Pro209Leu (P209L) is one of ten BAG3 mutations identified in human disease to date. Hypothesis: Cardiac BAG3 P209L expression inhibits CASA, evidenced by less autophagic flux of misfolded proteins. Methods: Cardiac specific transgenic mice with alphaMHC-driven human Bag3P209L were created and analyzed functionally over 12 months. Histological analysis of apoptosis (TUNEL), pre-amyloid oligomers (PAO), and fibroblasts were performed in parallel with transmission electron microscopy (TEM) and molecular analysis of autophagy and mitochondrial dynamics. Results: Starting at 8 months, Bag3 P209L Tg+ hearts had significantly depressed systolic function. By 12 months, significant deficits in both diastolic and systolic function were identified, along with increased number of fragmented mitochondria and significant alterations in genes regulating mitochondrial fusion (Opa1) and Fission (Drp1). Immunofluorescence analysis revealed no differences in apoptosis (TUNEL) or autophagic flux (LC3II). But increased levels of cardiomyocyte pre-amyloid oligomers (PAO) were identified by confocal immunofluorescence. As PAO proteotoxic intermediates found in neurodegenerative diseases reportedly activate p38 MAPK, we assayed BAG3 P209L Tg+ hearts and found a significant ~50% increase in phospho-p38/p38. Conclusion: As increased activated p38 activity has negative inotropic and restrictive diastolic effects in vivo, we conclude that inhibiting p38 activity in BAG3 P209L patients may attenuate and/or delay the onset of heart failure. Studies are underway testing this hypothesis using specific inhibitors of P38 and downstream signaling pathways in vivo.
Safety and efficacy of Ac-225-PSMA-617 in metastatic castration resistant prostate cancer (mCRPC) after failure of Lu-177-PSMA
Authors: R.L. Tauber, B. Feuerecker, K. Knorr, A. Beheshti, C. Seidl, C. D’Alessandria, F. Bruchertseifer, M. Retz, J.E. Gschwend, W. Weber, A. Morgenstern, M. Eiber
Journal: Annals of Oncology (2019)
The acetyltransferase GCN5 maintains ATRA-resistance in non-APL AML
Authors: Melanie Kahl, Annamaria Brioli, Martin Bens, Florian Perner, Anne Kresinsky, Ulf Schnetzke, Anna Hinze, Yordan Sbirkov, Sven Stengel, Giorgia Simonetti, Giovanni Martinelli, Kevin Petrie, Arthur Zelent, Frank-Dietmar Böhmer, Marco Groth, Thomas Ernst, Florian H. Heidel, Sebastian Scholl, Andreas Hochhaus, Tino Schenk
Journal: Leukemia (2019)
Inhibition of the PI3K pathway in HER2-positive gastric cancer
Authors: S. Toomey, M.J. Mezynski, A. Farrelly, P. Armstrong, J. McAuley, C. Holohan, Y.Y. Elamin, S. Rafee, J. Workman, M. Cremona, L. Grogan, O.S. Breathnach, P.G. Morris, J. Fay, E. Kay, B.T. Hennessy
Journal: Annals of Oncology (2019)
Pembrolizumab (Pem) in recurrent high-grade glioma (HGG) patients with mismatch repair deficiency (MMRd): An observational study
Authors: M. Caccese, M. Simonelli, M. Fassan, M. Padovan, P. Persico, L. Bellu, A. Dipasquale, M.P. Gardiman, S. Indraccolo, V. Zagonel, G. Lombardi
Journal: Annals of Oncology (2019)
Low 68Ga–PSMA PET/CT Uptake in Chronic Intramuscular Nodular Fasciitis
Authors: Nicolas Plouznikoff, Carlos Artigas, Ioannis Karfis, Patrick Flamen
Journal: Clinical Nuclear Medicine (2019)

Abstract Nodular fasciitis is an uncommon benign mass-forming myofibroblastic proliferation, most frequently found in the upper limbs, with only rare intramuscular cases. We describe herein a case of chronic nodular fasciitis of the left triceps muscle with a low 68 Ga-labeled prostate-specific membrane antigen (PSMA) ligand uptake on PET/CT. 68 Ga-PSMA ligands bind to PSMA-expressing prostate cancer cells, but uptake has also been demonstrated in other solid neoplasms and various benign lesions. Nodular fasciitis should be included in the differential diagnosis of soft tissue lesions with variable 68 Ga-PSMA uptake.
METTL3-mediated m<sup>6</sup>A modification of HDGF mRNA promotes gastric cancer progression and has prognostic significance
Authors: Qiang Wang, Chen Chen, Qingqing Ding, Yan Zhao, Zhangding Wang, Junjie Chen, Zerun Jiang, Yan Zhang, Guifang Xu, Jingjing Zhang, Jianwei Zhou, Beicheng Sun, Xiaoping Zou, Shouyu Wang
Journal: Gut (2019)

Objective N 6 -methyladenosine (m 6 A) RNA methylation and its associated methyltransferase METTL3 are involved in tumour initiation and progression via the regulation of RNA function. This study explored the biological function and clinical significance of METTL3 in gastric cancer (GC). Design The prognostic value of METTL3 expression was evaluated using tissue microarray and immunohistochemical staining analyses in a human GC cohort. The biological role and mechanism of METTL3 in GC tumour growth and liver metastasis were determined in vitro and in vivo. Results The level of m 6 A RNA was significantly increased in GC, and METTL3 was the main regulator involved in the abundant m 6 A RNA modification. METTL3 expression was significantly elevated in GC tissues and associated with poor prognosis. Multivariate Cox regression analysis revealed that METTL3 expression was an independent prognostic factor and effective predictor in human patients with GC. Moreover, METTL3 overexpression promoted GC proliferation and liver metastasis in vitro and in vivo. Mechanistically, P300-mediated H3K27 acetylation activation in the promoter of METTL3 induced METTL3 transcription, which stimulated m 6 A modification of HDGF mRNA, and the m 6 A reader IGF2BP3 then directly recognised and bound to the m 6 A site on HDGF mRNA and enhanced HDGF mRNA stability. Secreted HDGF promoted tumour angiogenesis, while nuclear HDGF activated GLUT4 and ENO2 expression, followed by an increase in glycolysis in GC cells, which was correlated with subsequent tumour growth and liver metastasis. Conclusions Elevated METTL3 expression promotes tumour angiogenesis and glycolysis in GC, indicating that METTL3 expression is a potential prognostic biomarker and therapeutic target for human GC.